LLY

737.06

+2.22%↑

JNJ

149.44

+1.99%↑

UNH

270.56

-12.95%↓

ABBV

181.13

+2.05%↑

NVO

65.88

+2.58%↑

LLY

737.06

+2.22%↑

JNJ

149.44

+1.99%↑

UNH

270.56

-12.95%↓

ABBV

181.13

+2.05%↑

NVO

65.88

+2.58%↑

LLY

737.06

+2.22%↑

JNJ

149.44

+1.99%↑

UNH

270.56

-12.95%↓

ABBV

181.13

+2.05%↑

NVO

65.88

+2.58%↑

LLY

737.06

+2.22%↑

JNJ

149.44

+1.99%↑

UNH

270.56

-12.95%↓

ABBV

181.13

+2.05%↑

NVO

65.88

+2.58%↑

LLY

737.06

+2.22%↑

JNJ

149.44

+1.99%↑

UNH

270.56

-12.95%↓

ABBV

181.13

+2.05%↑

NVO

65.88

+2.58%↑

Search

Clearside Biomedical Inc

Atidarymo kaina

0.85 -2.3

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.83

Max

0.89

Pagrindiniai rodikliai

By Trading Economics

Pajamos

383K

-7.3M

Pardavimai

-732K

306K

Pelnas, tenkantis vienai akcijai

-0.1

Pelno marža

-2,387.582

Darbuotojai

32

EBITDA

508K

-4.6M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+544.44% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-11

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-9.3M

69M

Ankstesnė atidarymo kaina

3.15

Ankstesnė uždarymo kaina

0.85

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Clearside Biomedical Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-14 23:40; UTC

Karštos akcijos

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

2025-05-14 23:33; UTC

Pagrindinės rinkos jėgos

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

2025-05-14 23:25; UTC

Pagrindinės rinkos jėgos

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

2025-05-14 23:25; UTC

Uždarbis

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

2025-05-14 22:58; UTC

Uždarbis

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

2025-05-14 21:35; UTC

Uždarbis

Cisco Systems Names Patterson as CFO, Patel as President

2025-05-14 23:59; UTC

Rinkos pokalbiai

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

2025-05-14 23:49; UTC

Rinkos pokalbiai

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

2025-05-14 23:48; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-05-14 23:48; UTC

Rinkos pokalbiai

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

2025-05-14 23:47; UTC

Rinkos pokalbiai

Gold Gains on Possible Technical Recovery -- Market Talk

2025-05-14 23:34; UTC

Įsigijimai, susijungimai, perėmimai

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

2025-05-14 23:10; UTC

Uždarbis

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

2025-05-14 23:07; UTC

Uždarbis

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

2025-05-14 23:00; UTC

Svarbiausios naujienos

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

2025-05-14 22:43; UTC

Uždarbis

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

2025-05-14 22:34; UTC

Uždarbis

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

2025-05-14 22:33; UTC

Uždarbis

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

2025-05-14 22:30; UTC

Uždarbis

Xero Did Not Declare a Dividend>XRO.AU

2025-05-14 22:30; UTC

Uždarbis

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

2025-05-14 22:30; UTC

Uždarbis

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

2025-05-14 22:30; UTC

Uždarbis

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

2025-05-14 22:28; UTC

Uždarbis

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

2025-05-14 22:28; UTC

Uždarbis

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

2025-05-14 22:27; UTC

Uždarbis

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

2025-05-14 22:27; UTC

Uždarbis

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

2025-05-14 22:23; UTC

Svarbiausios naujienos

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

2025-05-14 22:15; UTC

Uždarbis

Correction to Cisco Earnings Article -- WSJ

2025-05-14 21:48; UTC

Uždarbis

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

2025-05-14 21:37; UTC

Uždarbis

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Clearside Biomedical Inc Prognozė

Kainos tikslas

By TipRanks

544.44% į viršų

12 mėnesių prognozė

Vidutinis 5.8 USD  544.44%

Aukščiausias 8 USD

Žemiausias 4 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Clearside Biomedical Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

5

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

0.8417 / 0.8939Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Clearside Biomedical Inc

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.